A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context

A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancerResearch in context

Summary: Background: CDK4/6 inhibitors (CDK4/6i) are used for management of hormone receptor-positive (HR+) metastatic breast cancer (MBC), and activation of the RAS/MAPK and PI3K/AKT signalling pathways has been implicated in resistance to these agents. Pathogenic NF1 mutations (pNF1m) dysregulate...

Full description

Saved in:
Bibliographic Details
Main Authors: Maxwell R. Lloyd, Rosario Chica-Parrado, Caroline M. Weipert, Todd C. Knepper, Emily L. Podany, Fabiana Napolitano, Dan Ye, Chang-Ching Lin, Yasuaki Uemoto, Jiemin Liao, Claire Wegrzyn, Christine M. Walko, Lianne Y. Ryan, Jennifer C. Keenan, Arielle J. Medford, Shiyuan A. Liu, Gerburg M. Wulf, Katherine K. Clifton, Cynthia X. Ma, Hyo S. Han, Nicole Zhang, Leif W. Ellisen, Aditya Bardia, Carlos L. Arteaga, Ariella B. Hanker, Seth A. Wander
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:EBioMedicine
Subjects:
HR+ breast cancer
Metastatic breast cancer
NF1 mutation
CDK4/6 inhibitor
Precision medicine
Resistance mechanisms
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396425002725
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items